Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in primary sclerosing cholangitis.

Jennifer L Horsley-Silva1, Elizabeth J Carey1, Keith D Lindor2

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, USA.

The Lancet. Gastroenterology & Hepatology
|April 14, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same author

Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis.

Gastro hep advances·2026
Same author

Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?

European radiology·2026
Same author

The Nutrition Landscape in Chronic Liver Disease.

Digestive diseases and sciences·2026
Same author

Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.

Gut microbes·2026
Same author

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026

Primary sclerosing cholangitis (PSC) is a chronic liver disease often linked to inflammatory bowel disease. Current treatments are limited, with liver transplantation being the only option, and research is ongoing for new therapies.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic, progressive cholangiopathy often affecting men and associated with inflammatory bowel disease (IBD).
  • Its etiology is debated, with genetic and environmental factors potentially triggering immune-mediated responses.
  • PSC can manifest in various ways, including imaging abnormalities, biochemical changes, cholangiocarcinoma, or cirrhosis.

Purpose of the Study:

  • To review current knowledge on primary sclerosing cholangitis (PSC).
  • To summarize etiological theories and update on associated hepatobiliary malignancies.
  • To discuss emerging research areas for potential therapeutic interventions.

Main Methods:

  • This review synthesizes existing literature on PSC.

Related Experiment Videos

  • It includes an update on surveillance for hepatobiliary malignancies.
  • It discusses ongoing research into novel treatment strategies.

    • Main Results:

    • PSC presents with diverse clinical manifestations and can be challenging to differentiate from other cholangiopathies.
    • Patients with PSC have a poor prognosis, with common progression to cirrhosis and increased cancer risk, especially when associated with IBD.
    • Ursodeoxycholic acid may improve biochemical markers but does not alter disease progression.

    Conclusions:

    • Accurate diagnosis and differentiation of PSC are crucial for optimal disease surveillance.
    • Effective therapies to alter the disease course are lacking; liver transplantation is the only definitive treatment, with recurrence risk.
    • Further research is essential to identify effective treatments for PSC and improve patient outcomes.